Overview

Dendritic Cell Vaccine for Children and Adults With Sarcoma

Status:
Active, not recruiting
Trial end date:
2024-07-23
Target enrollment:
Participant gender:
Summary
The purpose if this study is to evaluate an investigational vaccine using patient-derived dendritic cells (DC), a type of white blood cell that helps fight infections in the body, (DC) (a vaccine made out of participants' own cells and tumor) to treat sarcoma.
Phase:
Phase 1
Details
Lead Sponsor:
Edward Ziga
Macarena De La Fuente, MD
Treatments:
Gemcitabine
Imiquimod
Vaccines